BBIO News and Press, BridgeBio Pharma Inc. From 08/03/23

- Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 (p<0.0001) and clinically me...

2023-08-02 10:45:00 ET Summary The US stock market (using the Russell 3,000 as a proxy) has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023. the peak market cap for the US stock market was $51.5 trillion...

- BridgeBio met with the U.S. Food and Drug Administration (FDA) to discuss the use of glycosylated αDG levels as a surrogate endpoint; based on this meeting, the Company believes there is potential to pursue Accelerated Approval in the U.S. for BBP-418 - BridgeBio has dosed the fi...

2023-07-26 09:11:45 ET Summary Tech stock momentum have experienced significant downturns over the past week, with Nasdaq-100 constituents glowing red. There are ample suggestions of sector rotation in play, which a variety of analytical filters also bear out. Spreads between ...

2023-07-21 10:44:42 ET Shares of BridgeBio Pharma (NASDAQ: BBIO) were up 90% for the week as of 10:25 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence . The biotech company, which focuses on therapies for oncology and genetic diseases, repo...

2023-07-17 18:42:44 ET Summary Primary endpoint met in BridgeBio Pharma, Inc.'s phase 3 ATTRibute-CM study, which used acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy; NDA filing expected before end of 2023. Results from the phase 3 ATTRibute-CM ...

2023-07-17 14:56:32 ET Summary BridgeBio Pharma, Inc. has reported encouraging results from its Phase 3 ATTRibute-CM study of acoramidis, a potential treatment for Transthyretin amyloid cardiomyopathy. The company's financial health is robust, with cash and equivalents increasing ...

2023-07-17 12:05:29 ET Shares of BridgeBio ( NASDAQ: BBIO ) shot up 80% in midday trading Monday after the biotech company said it plans to file for US regulatory approval of its drug acoramidis by the end of the year after releasing positive Phase 3 data for the drug in the treatme...

2023-07-17 10:07:51 ET Gainers: ProMIS Neurosciences ( PMN ) +149% . BridgeBio Pharma ( BBIO ) +62% . Acumen Pharmaceuticals ( ABOS ) +60% . Healthcare Triangle ( HCTI ) +42% . argenx ( ARGX ) +30% . Losers: Apellis P...

2023-07-17 09:09:09 ET The stock market has been on a solid upward trajectory recently, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) has largely been leading the way. With so many stocks in high-growth areas like technology, the Nasdaq has been at the center of key trends driving s...